Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Liponucleotide-based therapy for ards

A CDP-, cytidine diphosphate technology, which is applied in the directions of non-active ingredients medical preparations, active ingredients-containing medical preparations, drug combinations, etc., can solve problems such as not showing benefits

Inactive Publication Date: 2019-03-15
OHIO STATE INNOVATION FOUND
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, recent trials of surfactant replacement therapy in human ARDS patients have been inconclusive or have shown no benefit

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Liponucleotide-based therapy for ards
  • Liponucleotide-based therapy for ards
  • Liponucleotide-based therapy for ards

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0078] figure 1 is a graph showing the effect of infection on ATII cells DPPC(16:0 / 16:0) surfactant. #=P<0.001.

[0079] figure 2 is a graph showing the effect of infection on ATII cells with DPPG (16:0 / 16:0) surfactant. *=P<0.05, #=P<0.001.

[0080] image 3 is a graph showing the effect of infection on ATII cells PE(16:0 / 18:2) surfactant. #=P<0.001.

[0081] Figure 4 is a graph showing the effect of infection on BALF phospholipid glycerol. #=P<0.001.

[0082] Figure 5 is a schematic diagram showing DPPC synthesis of the CDP-choline (Kennedy) pathway.

[0083] Figure 6 is a graph showing the effect of infection on DAG (18:1 / 18:2) of ATII cells. *=P<0.05, #=P<0.001.

[0084] Figure 7 is a graph showing the effect of infection on ATII cells choline-P(18:1 / 18:2).

[0085] Figure 8 is a graph showing the effect of infection on CDP-choline in ATII cells.

[0086] Figure 9 is a schematic diagram showing the treatment method.

[0087] Figure 10 is a graph...

example 2

[0093] Table 2 shows the effect of combinations of CDP-conjugated precursors.

example 3

[0095] Figure 14 is a set of three transmission electron micrographs showing the effect of CDP-choline treatment on the ultrastructure of ATII cell lamellar bodies (composed of surfactant lipids and proteins). Lamellar bodies in ATII cells from influenza A / WSN / 33(H1N1)-infected mice were smaller and had abnormal lamellae relative to mock-infected controls. CDP-choline treatment improved lamellar body morphology. Mi in ATII cells from CDP-choline treated mice were also more electron dense and had more normal cristae.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Compositions and method are therefore disclosed for treating ARDS. In particular, disclosed a composition that contains one, two, or more cytidine diphosphate (CDP)-conjugated precursors selected fromthe group consisting of CDP-choline, CDP-ethanolamine, and CDP-diacylglycerol (CDP-DAG) in a pharmaceutically acceptable carrier for use in treating ARDS.

Description

[0001] relevant application data [0002] This application claims the benefit of US Provisional Application No. 62 / 355,096, filed June 27, 2016, which is hereby incorporated by reference in its entirety. Background technique [0003] Acute respiratory distress syndrome (ARDS, also known as acute lung injury or acute hypoxic respiratory failure) is a clinical syndrome characterized by acute episodes of severely impaired alveolar gas exchange. ARDS can be caused by direct lung injury (infection, inhalation of toxic gases, etc.) or as an indirect result of trauma, sepsis, or other physical injury. In the United States, approximately 200,000 human cases of ARDS occur each year. ARDS can also develop in other animals. Once ARDS has developed, the only treatment option is nontargeted supportive management in the ICU. Currently, approximately 40% of human patients with any form of ARDS die, and many more suffer from severe pulmonary function deficits that reduce quality of life. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/513A61K31/70
CPCA61P11/00A61K31/7068A61K47/549A61K2300/00A61K47/18A61K47/24A61K47/26C07H19/20A61K47/50
Inventor 伊恩·克里斯托弗·戴维斯
Owner OHIO STATE INNOVATION FOUND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com